Here is the side by side. Pretty lame from our

New Post Public Reply Private Reply Replies (1) Message Board
CaptnAmerca
935
Here is the side by side. Pretty lame from our perspective, but not like the Landstreet debacle, or Meg Tirrell just moving on to the next non-leronlimab question w/o a mention.

Original Version

Quote:
CytoDyn, a Vancouver, Wash., biotechnology company, recently applied to the U.S. Food and Drug Administration to test its experimental drug, leronlimab, on 102 long Covid patients, says Scott A. Kelly, chief medical officer of the company.

Leronlimab, a monoclonal antibody administered through subcutaneous injections, was developed as an HIV drug. When the pandemic hit, the company shifted to Covid-19. The same receptor that allows HIV to enter cells is also important in regulating immune cells; some doctors believe long-term Covid symptoms are caused by the immune system going haywire. The company has recently tested the treatment in severe Covid patients as well as in mild to moderate cases, some of which were long-haul patients.

Some patients with long-term symptoms reported their brain fog and cognition issues improving after treatment. "When we started to see these patients saying the brain fog was clearing, we were encouraged," says Dr. Kelly. A new trial would test the drug specifically on long-haul patients.
Dr. Kelly says they believe leronlimab may be alleviating brain inflammation. Leronlimab binds to a cell receptor that contributes to the regulation of immune cells that sometimes flood an area and destroy tissue. Blocking that receptor may slow down the inflammatory response, which some scientists believe is triggering problems in long Covid patients.

"We are hopeful we can control the neuroinflammation in the brain which we think causes a lot of these problems with autonomic dysfunction, fatigue, brain fog," says Dr. Kelly. The company says patients haven't reported significant side effects in the clinical trials they've done for Covid and HIV.

Dr. Kelly says the interest in such a treatment is tremendous. "I get emails every day about wanting to participate in the trial," he says. Among them is Patrick Varnes, a 41-year-old financial director in Atlanta who was diagnosed with Covid at the end of June. Nearly six months later he continues to have shortness of breath, fatigue and headaches. "I've had
shortness of breath every single day," says Mr. Varnes. Before Covid-19, Mr. Varnes was a fitness buff. He went to a CrossFit gym five days a week. Now, he can't do much more than go on a walk.

He heard about leronlimab from an online support group and reached out to Christopher Recknor, a Gainesville, Ga., physician who runs clinical trials for CytoDyn. Mr. Varnes did a pre-screening; if the FDA approves a trial, he'll be able to join it, says Dr. Recknor.

Mr. Varnes says he's tried nearly 30 different supplements, acupuncture and a steroid. "After six months of living inan internal prison, I need to try it," says Mr. Varnes. "I really, really hope it works."


EDITED VERSION

Quote:
Before Covid-19, Mr. Varnes was a fitness buff. He went to a CrossFit gym five days a week. Now, he can't do much more than go on a walk. "I've had shortness of breath every single day," says Mr. Varnes.
He heard about a drug called leronlimab from an online support group and reached out to a physician who runs clinical trials for CytoDyn, a Vancouver, Wash., biotechnology company. It recently applied to the U.S. Food and Drug Administration to test its experimental drug, leronlimab, on 102 long Covid patients, says Scott A. Kelly, chief medical officer of the company.

Leronlimab, a monoclonal antibody administered through subcutaneous injections, was developed as an HIV drug. It hasn't been FDA approved for HIV or for Covid. The company has recently tested the treatment in severe Covid patients as well as in mild to moderate cases, some of which were long-haul patients. The research is preliminary; there is no published data from human trials validating the results. A new trial would test the drug specifically on long-haul patients. The company says patients haven't reported significant side effects in the clinical trials they've done for Covid and HIV.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Penetron Strengthens Midwest, Central USA Support Team

Updated Category News Views 3

Expansion of Penetron's Engineering Support Eyes are on the Midwest and Central USA as Penetron makes a strategic move to bolster their technical support dream team. They've snagged Sean Allison, a heavyweight with more than three decades' worth of grit and know-how from the construction battlefield. Sean, now stationed in the heart of America's Dairyland—Green Bay,...

Continue Reading
PrimeBOT Shines at IFA 2026 with Innovative Awards

Updated Category News Views 6

A New Chapter in Home Robotics In today's tech-centric world, newcomers often confuse flash with substance. But every now and then, you catch a glimpse of something that might just change how the world spins. At this year's IFA 2026, PrimeBOT didn't just dip its toes into the limelight—it cannonballed right in, drumming up some serious buzz with its PrimeBOT T1 and...

Continue Reading
Freeport-McMoRan Hit with Legal Probe: What's Next?

Updated Category News Views 4

Investigating the Movers and Shakers at Freeport When legal hawks like Kahn Swick & Foti, LLC sink their teeth into something, you can bet it's not just to nibble. These folks have jumped headfirst into probing Freeport-McMoRan Inc. (NYSE:FCX), ready to dismantle any smoke screens that might have been thrown up after the unfortunate Grasberg Block Cave mine incident. The...

Continue Reading
Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Updated Category News Views 3

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...

Continue Reading
Kansas City's Haunts Condense Season to 13 Nights

Updated Category News Views 2

A Scary Short Season Takes Center Stage Hold onto your ghost hats, folks! The Kansas City haunt legends are shaking things up with a shorter scare season. This October, the infamous Edge of Hell and The Beast attractions are packing in the frights over just 13 nights, shifting their schedule due to rising September temperatures. Now, ain't that something? For their 52nd...

Continue Reading
Unlocking Insights: South Chicagoland Home Inspections

Updated Category News Views 1

Sizing Up South Chicagoland Homes: What Really Gets Inspected In the world of real estate transactions, home inspections stand like grizzled veterans, proudly scrutinizing every nook and cranny before the ink dries on a property deed. Here in South Chicagoland, where the echoes of every frigid winter and sweltering summer linger, the process becomes a lifeline for buyers...

Continue Reading
Dr. Rashedi Reveals Laughing Gas Safety for Kids

Updated Category News Views 3

Why Laughing Gas is a Game-Changer in Pediatric Dentistry You ever seen a kid freeze up like a deer in headlights at the dentist's office? I'm telling you, it's not just the sweet tooth nightmare but often the fear of that cold, intimidating chair. But let's talk about a game-changer: laughing gas or, known in the trade as nitrous oxide. Keeping Anxiety at Bay: The Role...

Continue Reading
Papa John's Faces Securities Class Action Over Missteps

Updated Category News Views 3

Papa John's Stock Takes a Nosedive Here's a hot potato for you—Papa John's International, Inc. (NASDAQ: PZZA) just got slapped with a securities class action. This ain't a pie you want a slice of, not after the dough they lost in a day's trading frenzy. On August 6, our friends at Papa John's sent their investors scrambling as their stock tumbled from $29.75 to a stark...

Continue Reading
Dreame Unveils Vast AI Product Range at IFA 2026

Updated Category News Views 0

Overnight Sensation or Future Staple? I wonder if Dreame's top brass woke up sweating or smiling after their big reveal at IFA 2026. A buffet of over 100 products across 16 categories is no small feat, especially when you're banking on technologies developed over nine years. But let's cut through the noise—does this showcase promise innovation or just smoke and mirrors?...

Continue Reading
LG's High-Purity RGB Displays Shine at IFA 2026

Updated Category News Views 2

LG's Latest Dazzler: RGB Evo Takes the Spotlight LG has never been shy about setting standards in the home entertainment sector, and they’re doing it again at IFA 2026 with their high-purity RGB displays. Make no mistake, when LG rolls out a massive LCD TV certified by TÜV Rheinland for color purity, every other home theater manufacturer is scrambling to keep up. "LG...

Continue Reading

Top 5 Most Recently Viewed Articles

Labor Market Resilience: Jobless Claims and Economic Growth Insights

Updated Category News Views 169

The U.S. economy has shown remarkable resilience, with recent data indicating a 3% expansion in the economic landscape. This figure comes from the latest estimates, marking a considerable increase from the first quarter's growth of 1.4%. The consistency of this performance is notable, representing eight consecutive quarters of growth, showcasing the strength embedded in...

Continue Reading
W Straits Limited and GLAC Enhance Collaboration for Growth

Updated Category News Views 116

W Straits Limited and Global Lights Acquisition Corp. Move Forward W Straits Limited, a prominent player in the fintech industry, is currently in discussions with Global Lights Acquisition Corp (NASDAQ: GLAC). The two companies are making significant strides in their negotiations for a potential business combination that promises to reshape their respective industries....

Continue Reading
Bivial AG Revolutionizes Business Payments with Award Win

Updated Category News Views 156

Bivial AG Shines at PayTech Awards 2025 Bivial AG, a leading Swiss fintech innovator, proudly announces its recognition for the "Best Use of Tech in Business Payments" at the prestigious PayTech Awards 2025. This esteemed accolade emphasizes Bivial's significant contributions to enhancing transactional banking for digital enterprises around the globe. A Cutting-Edge...

Continue Reading
Legal Actions Arise as StubHub Faces IPO Disclosure Issues

Updated Category News Views 147

Understanding the StubHub IPO Controversy StubHub Holdings, Inc. (NYSE: STUB), a leading player in the ticket resale market, is now facing serious legal challenges following its recent initial public offering (IPO). A proposed securities class action has been filed against the company, primarily questioning the accuracy of its IPO disclosures. Investors Taking Action...

Continue Reading
Piedmont Office Realty Trust Announces Q3 2024 Earnings Call

Updated Category News Views 59

Piedmont Office Realty Trust Sets Date for Q3 2024 Financial Results Piedmont Office Realty Trust, Inc. (NYSE: PDM) has recently revealed that it will announce its third quarter financial results soon. The anticipated report is scheduled for release on a Thursday following the close of trading on the New York Stock Exchange. Conference Call Details In an effort to engage...

Continue Reading